Related Experiment Videos
Plastic ELISA-on-a-chip based on sequential cross-flow chromatography.
Joung-Hwan Cho1, Seung-Mok Han, Eui-Hwan Paek
1Graduate School of Biotechnology, Korea University, Sungbuk-ku, Seoul.
Analytical Chemistry
|February 2, 2006
Summary
A novel ELISA-on-a-chip device utilizing enzyme-linked immunosorbent assay (ELISA) technology was developed for rapid cardiac troponin I (cTnI) detection. This microfluidic chip demonstrates high sensitivity and accuracy comparable to established systems.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Point-of-Care Diagnostics
Background:
- Enzyme-linked immunosorbent assays (ELISA) are crucial for detecting biomarkers like cardiac troponin I (cTnI).
- Conventional ELISA methods can be time-consuming and require laboratory infrastructure.
- There is a need for rapid, sensitive, and portable diagnostic tools for cardiac markers.
Purpose of the Study:
- To develop and evaluate an ELISA-on-a-chip device for quantifying cardiac troponin I (cTnI).
- To integrate ELISA principles into a microfluidic platform for point-of-care applications.
- To assess the analytical performance and diagnostic accuracy of the developed chip.
Main Methods:
- A microfluidic chip was designed with orthogonal channels for cross-flow chromatography.
- An immunostrip incorporating horseradish peroxidase (HRP)-labeled antibodies for cTnI detection was integrated into the chip.
- Enzyme substrate was introduced, and colorimetric detection was performed using a digital camera-based system.
Main Results:
- The ELISA-on-a-chip achieved a detection limit of approximately 0.1 ng/mL for cTnI.
- A quantification limit of 0.25 ng/mL was established for the assay.
- The chip demonstrated performance correlating with a reference system (Beckman Coulter Access) within a 2.5-fold discrepancy.
Conclusions:
- The developed ELISA-on-a-chip is a promising tool for rapid and sensitive cTnI detection.
- The microfluidic design and enzyme-based detection enable efficient immunoassays.
- This platform holds potential for point-of-care cardiac marker diagnostics.